These key molecular initiating events with PPARα activation are central to the disruption of most pathways associated with obesity, diabetes, high cholesterol, and other metabolic-dysfunction-associated fatty liver diseases (MAFLDs). This evidence concerns the gene PPARA and obesity disorder.